1. Cell Cycle/DNA Damage
  2. Deubiquitinase

Deubiquitinase

Deubiquitinases (DUBs) are a large group of proteases that cleave ubiquitin from proteins and other molecules. Ubiquitin is attached to proteins in order to regulate the degradation of proteins via the proteasome and lysosome; coordinate thecellular localisation of proteins; activate and inactivate proteins; and modulate protein-protein interactions. DUBs can reverse these effects by cleaving the peptide or isopeptide bond between ubiquitin and its substrate protein. In humans there are nearly 100 DUB genes, which can be classified into two main classes: cysteine proteases and metalloproteases. The cysteine proteases comprise ubiquitin-specific proteases (USPs), ubiquitin C-terminal hydrolases (UCHs), Machado-Josephin domain proteases (MJDs) and ovarian tumour proteases (OTU). The metalloprotease group contains only the Jab1/Mov34/Mpr1 Pad1 N-terminal+ (MPN+) (JAMM) domain proteases. DUBs play several roles in the ubiquitin pathway. One of the best characterised functions of DUBs is the removal of monoubiqutin and polyubiquitin chainsfrom proteins.

Deubiquitinase Related Products (19):

Cat. No. Product Name Effect Purity
  • HY-13453
    BAY 11-7082 Inhibitor 99.64%
    BAY 11-7082 is a NF-κB inhibitor.
  • HY-50737A
    DUBs-IN-2 Inhibitor 99.08%
    DUBs-IN-2 is a potent and highly selective deubiquitinase USP8 inhibitor with IC50 of 0.28 μM.
  • HY-13264
    WP1130 Inhibitor 99.72%
    WP1130 inhibits the autoactivation of Bcr-Abl by inducing its rapid down-regulation with IC50 of 1.8 μM.
  • HY-13487
    USP7/USP47 inhibitor Inhibitor 98.17%
    USP7/USP47 inhibitor is a potent and dual inhibitor of USP7/USP47 with IC50s of 0.42 uM(USP7) and 1.0 uM(USP47).
  • HY-13865
    P 22077 Inhibitor 98.50%
    P22077 is a potent inhibitor of ubiquitin-specific protease (USP) 7 (EC50=8.6 uM), P22077 also inhibits the closely related deubiquitinase (DUB) USP47.
  • HY-17540
    HBX 19818 Inhibitor
    HBX 19818 is a selective USP7 inhibitor with IC50 of 28.1 uM .
  • HY-100708
    NSC632839 Inhibitor 98.35%
    NSC632839 is a nonselective isopeptidase inhibitor, which inhibits USP2, USP7, and SENP2 with EC50s of 45±4 μM, 37±1 μM, and 9.8±1.8 μM, respectively.
  • HY-100900
    ML364 Inhibitor 99.81%
    ML364 is an USP2 inhibitor extracted from patent WO 2016134026 A1, compound example 10G.
  • HY-17543
    ML-323 Inhibitor 98.50%
    ML-323 is a reversible, potent USP1-UAF1 inhibitor with IC50 of 76 nM in a Ub-Rho assay.
  • HY-15667
    P005091 Inhibitor 99.90%
    P005091 is a selective and potent inhibitor of ubiquitin-specific protease 7 (USP7) with EC50 of 4.2 μM and the closely related USP47.
  • HY-12471
    VLX1570 Inhibitor >98.0%
    VLX1570 is a competitive inhibitor of proteasome DUB activity with IC50 ranging from 4.2 uM to 8.6 uM.
  • HY-13814
    PR-619 Inhibitor
    PR-619 is a broad-range DUB inhibitor with potential for further development as a chemotherapeutic agent in cancer therapy.
  • HY-13989
    b-AP15 Inhibitor 98.02%
    b-AP15 is a specific inhibitor of the deubiquitinating enzymes UCHL5 and Usp14.
  • HY-15757
    SJB2-043 Inhibitor 99.30%
    SJB2-043 is one of analogs/derivatives of C527, which is a novel and potent USP1 (ubiquitin-specific protease 1) inhibitor.
  • HY-80012
    SJB3-019A Inhibitor >98.0%
    SJB3-019A is a potent and novel USP1 inhibitor, 5 times more potent than SJB2-043 in promoting ID1 degradation and cytoxicity in K562 cells with IC50 of 0.0781 μM.
  • HY-50737
    DUBs-IN-3 Inhibitor 99.40%
    DUBs-IN-3 is a potent deubiquitinase enzyme inhibitor, extracted from the reference, compound 5c, has IC50s of 3.1 μM and > 100 μM for USP8 and USP7, respectively.
  • HY-18637
    LDN-57444 Inhibitor
    LDN-57444 is a potent, reversible, competitive and active site-directed inhibitor of UCHL1 with Ki of 0.4 uM.
  • HY-50736
    DUBs-IN-1 Inhibitor 99.46%
    DUBs-IN-1 is a potent deubiquitinase enzyme inhibitor with IC50s of 18 uM/0.71 uM for USP7/USP8 respectively.
  • HY-16709
    USP7-IN-1 Inhibitor
    USP7-IN-1 is a novel selective and reversible inhibitor of USP7 with IC50 of 33 uM; less or no inhibition on USP5, USP8, Uch-L1, Uch-L3 and Caspase(IC50>200 uM); HCT116 cell viability GI50 is 67 uM.